Gene Editing Stocks to Watch in 2025 News ad
Gene editing started 2024 with a bang in the medical sector but ended the year with a whimper. It all started with the FDA approval of the first CRSPR-based gene therapy for sickle cell anemia (SCA) called Casgevy, developed by Vertex Pharmaceuticals Inc. NASDAQ: VRTX. Sickle cell anemia is a disease in which red blood … Read more